Dr. John T. Baber SR., MD
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Medical school
- University of Arkansas College of Medicine (1975)
- Years since graduation
- 51
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 498
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1975Medical school: University of Arkansas College of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
AR license C4911
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Chi St. Vincent Hospital Hot Springs Hot Springs, AR
- Chi-St Vincent Infirmary Little Rock, AR
Medical groups
- St Vincent Medical Group (240 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 498
- Services billed
- 1,148
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 198 | 145 |
| New patient office or other outpatient visit, 45-59 minutes | 160 | 160 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 108 | 105 |
| Established patient office or other outpatient visit, 20-29 minutes | 94 | 82 |
| Diagnostic exam of large bowel using a flexible endoscope | 90 | 89 |
| New patient office or other outpatient visit, 30-44 minutes | 79 | 79 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 67 | 34 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 47 | 46 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 39 | 39 |
| Destruction of polyp or growth of large bowel using a flexible endoscope | 38 | 38 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Pantoprazole Sodium Other prescribers in Little Rock, AR | 394 |
| Linzess (linaclotide) Other prescribers in Little Rock, AR | 145 |
| Dicyclomine Hcl Other prescribers in Little Rock, AR | 109 |
| Sucralfate Other prescribers in Little Rock, AR | 76 |
| Ondansetron Hcl Other prescribers in Little Rock, AR | 45 |
| Colestipol Hcl Other prescribers in Little Rock, AR | 44 |
| Dexlansoprazole Dr (dexlansoprazole) Other prescribers in Little Rock, AR | 41 |
| Metoclopramide Hcl Other prescribers in Little Rock, AR | 33 |
| Omeprazole Other prescribers in Little Rock, AR | 31 |
| Stelara (ustekinumab) | 30 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 14 companies reported 57 payments worth $866 in total to this clinician.
| Pfizer Inc. | $229 |
|---|---|
| Janssen Biotech, Inc. | $191 |
| AbbVie Inc. | $175 |
| Ipsen Biopharmaceuticals, Inc | $61.10 |
| Lilly USA, LLC | $49.68 |
| Aimmune Therapeutics, Inc. | $33.34 |
| Medtronic, Inc. | $20.24 |
| Gilead Sciences, Inc. | $18.02 |
| Food and Beverage | $782 |
|---|---|
| Education | $84.00 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Dec 2, 2025 | Education TREMFYA · Immunology · in-kind | $84.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 4 companies. The companies reported $115,494 in research payments for these studies, mostly to the institutions running them.
- Evaluating the safety and efficacy of tradipitant vs. placebo in idiopathic and diabetic gastroparesis
Vanda Pharmaceuticals Inc. - EoE-201
Phathom Pharmaceuticals, Inc. - A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
Eli Lilly and Company · Active, not recruiting · NCT06598943 - Single-patient expanded access protocol for tradipitant in a single patient with gastroparesis
Vanda Pharmaceuticals Inc. - Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC)
AbbVie Inc. · Completed · NCT04026113 - Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C
AbbVie Inc. - Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C
AbbVie Inc. · Completed · NCT04166058 - LIN-MD-66 - Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.